Uncover key drivers, emerging technologies, and competitive movements shaping the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market from 2026–2035 with trusted insights from The Business Research Company
How is the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market size predicted to change over the forecast window of 2026–2035?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size has demonstrated robust growth in recent years. This market is projected to expand from $8.43 billion in 2025 to $8.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. The historical expansion of this market can be ascribed to several factors, including the prevalence of prostate cancer, the development of hormone therapy resistance, continuous innovation in oncology drugs, the provision of hospital-based cancer care, and an increasing aging male population.
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market is anticipated to experience robust expansion in the upcoming years. This market is projected to reach $11.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. The observed growth during the forecast period can be primarily attributed to factors such as biomarker-guided treatment approaches, cutting-edge targeted therapies, the increasing embrace of oral oncology, an expanding oncology drug pipeline, and the rise of personalized cancer care. Key trends expected over the forecast period encompass the escalating utilization of androgen receptor inhibitors, the proliferation of PARP inhibitor therapies, the broadening of combination treatment regimens, a heightened emphasis on precision oncology, and a general move towards oral oncology medications.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp
Which Drivers Are Contributing To The Expansion Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The increasing occurrence of prostate cancer is anticipated to fuel the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. Prostate cancer is defined as a malignancy that forms within the prostate gland, a minor gland in males situated beneath the bladder and anterior to the rectum. This rise in prostate cancer cases is linked to an aging population, given that the likelihood of developing the condition grows considerably with advancing age. Therapies for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) aid in managing prostate cancer by addressing advanced disease stages that no longer respond to standard hormone treatment. These treatments enhance patient results by decelerating the disease’s progression and alleviating symptoms, thus improving their quality of life. As an example, in October 2025, data from NHS Digital, a UK government body overseeing healthcare statistics, showed 58,137 new prostate cancer diagnoses in England during 2023, marking a 6 percent rise from 2022. Consequently, the increasing prevalence of prostate cancer is propelling the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.
What Segment Classifications Make Up The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals
Which Trends Are Guiding The Evolution Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
Major companies operating in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating on developing innovative products and securing approvals, such as dual-action tablets, to improve treatment efficacy and patient outcomes. Dual-action tablets are defined as advanced formulations that combine two therapeutic agents in a single dose to concurrently target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. For example, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Akeega, a novel tablet designed for the treatment of adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that integrates a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically targeting patients with BRCA mutations. When administered alongside prednisone, it significantly enhances radiographic progression-free survival (rPFS) compared to conventional hormonal therapy alone.
Which Key Market Players Are Investing In Expansion And Innovation Within The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Poised For Strategic Growth In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp
Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company
Prostate Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Urothelial Carcinoma Treatment Market Report 2026
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model